First Trust Nasdaq Pharmaceuticals ETF
$40.43−0.82 (−1.99%)
- 0.60%
- $1.1B
- +43.8%
- 0.70%
- 0.5M sh
- $41.22
- low $28.77high $43.52
The ETF.net FTXH Grade
B
Score 56 out of 100
- 6 of 9
Score 56 of 100 falls in the B band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.
Cost
The fund’s net expense ratio, ranked against its category.F21 out of 100Rank 8 of 9Mission
Whether the fund did what it promised, tested against its stated mandate.A75 out of 100Rank 3 of 6Risk
How the fund held up when markets fell: downside volatility, drawdowns and tail loss.B69 out of 100Rank 3 of 9Tradability
How easy the fund is to trade: daily volume, and how far its price strays from net asset value.B67 out of 100Rank 3 of 9Holdings
How concentrated the fund is, and how complete and current its disclosed holdings are.A73 out of 100Rank 3 of 9Durability
Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.A80 out of 100Rank 2 of 9
Our read on FTXH
BMost pharma funds just size positions by market cap. FTXH screens US pharma stocks for liquidity, then ranks and weights them on value, momentum and profitability, so the biggest drugmaker isn't automatically the biggest holding.
The fund seeks returns broadly matching the price and yield of the Nasdaq US Smart PharmaceuticalsTM Index before expenses. It uses an indexing approach intended to replicate that index’s holdings and weights, targeting 95% correlation, without assuring success.
Why people hold it
- Weights follow a factor scorecard (value, momentum, profitability) rather than company size, a different recipe from the plain cap-weighted pharma funds it sits beside.ftportfolios.com
- Stays in its lane: US pharmaceutical companies, not a broad health care blend of biotech, device makers and insurers.ftportfolios.com
- Live since 2016 with a few hundred million in assets, it changes hands actively and pays distributions quarterly.
- Index replication is the whole job here, and the fund has kept close to the Nasdaq US Smart Pharmaceuticals Index it advertises.ftportfolios.com
Worth knowing
- The screen costs money: 0.60% a year, above the pharma-ETF median and well above cap-weighted rivals PPH (0.36%) and XPH (0.35%).
- About 50 names in a single sector. Patent rulings, trial results and drug-pricing headlines land with full force.
- Factor weighting cuts both ways: the lineup can look quite different from a standard cap-weighted pharma benchmark, and behave differently too.
FTXH Holdings
- Stocks
- 51
- 55%
- ABBV
Sectors
- Health Care100.0%
Geography
- United States96.37%
- Ireland3.12%
- United Kingdom0.51%
FTXH Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
FTXH$14,379
Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | FTXH |
|---|---|
| Year to date | +25.8% |
| 1 month | +2.0% |
| 3 months | +7.7% |
| 1 year | +43.8% |
| 3 years | +19.0% |
| 5 years | +11.4% |
| 10 years | +9.1% |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | FTXH |
|---|---|---|
| 2026 YTD | +25.8% | |
| 2025 | +24.2% | |
| 2024 | +3.0% | |
| 2023 | −1.4% | |
| 2022 | +2.5% | |
| 2021 | +6.1% | |
| 2020 | +11.7% |
FTXH in the news
FTXH Dividends
- 0.70%
- $0.29
- $0.01 per share
- Quarterly
Distribution history
FTXH Risk
- 14.3%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.98
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −19.5%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.46
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
FTXH Cost
0.60%
FTXH0.60%
- The middle half of Pharma & Therapeutics funds
- Median 0.58%
7 of the 9 Pharma & Therapeutics funds charge less.
Other funds in Pharma & Therapeutics
- BPJPInvesco Pharmaceuticals ETFExpense ratio 0.58%1 year return +34.5%
- BPBPHPortfolio Building Block World Pharma and Biotech Index ETFExpense ratio 0.13%1 year return —
- COZEMRoundhill Investments - GLP-1 & Weight Loss ETFExpense ratio 0.59%1 year return +3.7%
- CTHNRAmplify Weight Loss Drug & Treatment ETFExpense ratio 0.59%1 year return +4.1%
- FPSILAdvisorShares Psychedelics ETFExpense ratio 1.84%1 year return +20.4%